![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GLCE |
Gene summary for GLCE |
![]() |
Gene information | Species | Human | Gene symbol | GLCE | Gene ID | 26035 |
Gene name | glucuronic acid epimerase | |
Gene Alias | HSEPI | |
Cytomap | 15q23 | |
Gene Type | protein-coding | GO ID | GO:0006022 | UniProtAcc | O94923 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26035 | GLCE | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.21e-07 | -3.83e-01 | 0.0155 |
26035 | GLCE | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.67e-05 | -4.89e-01 | -0.1808 |
26035 | GLCE | HTA11_696_2000001011 | Human | Colorectum | AD | 1.84e-04 | -3.64e-01 | -0.1464 |
26035 | GLCE | HTA11_6818_2000001021 | Human | Colorectum | AD | 9.42e-03 | -4.62e-01 | 0.0588 |
26035 | GLCE | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.79e-10 | -4.51e-01 | 0.3859 |
26035 | GLCE | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.63e-19 | -5.76e-01 | 0.3005 |
26035 | GLCE | A001-C-207 | Human | Colorectum | FAP | 1.39e-03 | -2.32e-01 | 0.1278 |
26035 | GLCE | A015-C-203 | Human | Colorectum | FAP | 1.13e-22 | -2.83e-01 | -0.1294 |
26035 | GLCE | A015-C-204 | Human | Colorectum | FAP | 6.92e-07 | -3.47e-01 | -0.0228 |
26035 | GLCE | A014-C-040 | Human | Colorectum | FAP | 9.22e-03 | -3.90e-01 | -0.1184 |
26035 | GLCE | A002-C-201 | Human | Colorectum | FAP | 2.35e-09 | -2.78e-01 | 0.0324 |
26035 | GLCE | A002-C-203 | Human | Colorectum | FAP | 3.33e-04 | -2.35e-01 | 0.2786 |
26035 | GLCE | A001-C-119 | Human | Colorectum | FAP | 3.64e-05 | -4.32e-01 | -0.1557 |
26035 | GLCE | A001-C-108 | Human | Colorectum | FAP | 4.23e-15 | -2.15e-01 | -0.0272 |
26035 | GLCE | A002-C-205 | Human | Colorectum | FAP | 1.16e-17 | -3.49e-01 | -0.1236 |
26035 | GLCE | A001-C-104 | Human | Colorectum | FAP | 1.29e-08 | -3.68e-01 | 0.0184 |
26035 | GLCE | A015-C-005 | Human | Colorectum | FAP | 2.14e-02 | -2.47e-01 | -0.0336 |
26035 | GLCE | A015-C-006 | Human | Colorectum | FAP | 5.88e-14 | -4.40e-01 | -0.0994 |
26035 | GLCE | A015-C-106 | Human | Colorectum | FAP | 2.18e-07 | -2.57e-01 | -0.0511 |
26035 | GLCE | A002-C-114 | Human | Colorectum | FAP | 4.33e-20 | -5.94e-01 | -0.1561 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
GO:00067901 | Colorectum | SER | sulfur compound metabolic process | 73/2897 | 339/18723 | 1.75e-03 | 1.81e-02 | 73 |
GO:00067902 | Colorectum | MSS | sulfur compound metabolic process | 85/3467 | 339/18723 | 1.52e-03 | 1.39e-02 | 85 |
GO:0009101 | Colorectum | FAP | glycoprotein biosynthetic process | 63/2622 | 317/18723 | 2.31e-03 | 1.86e-02 | 63 |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:00442725 | Esophagus | ESCC | sulfur compound biosynthetic process | 96/8552 | 148/18723 | 1.86e-06 | 2.16e-05 | 96 |
GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
GO:0006029 | Esophagus | ESCC | proteoglycan metabolic process | 48/8552 | 79/18723 | 4.93e-03 | 1.89e-02 | 48 |
GO:0030166 | Esophagus | ESCC | proteoglycan biosynthetic process | 35/8552 | 56/18723 | 8.30e-03 | 2.94e-02 | 35 |
GO:0006024 | Esophagus | ESCC | glycosaminoglycan biosynthetic process | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
GO:0006023 | Esophagus | ESCC | aminoglycan biosynthetic process | 47/8552 | 79/18723 | 9.29e-03 | 3.23e-02 | 47 |
GO:0030201 | Esophagus | ESCC | heparan sulfate proteoglycan metabolic process | 21/8552 | 31/18723 | 1.10e-02 | 3.70e-02 | 21 |
GO:00067904 | Liver | NAFLD | sulfur compound metabolic process | 58/1882 | 339/18723 | 3.79e-05 | 9.38e-04 | 58 |
GO:0044272 | Liver | NAFLD | sulfur compound biosynthetic process | 28/1882 | 148/18723 | 7.52e-04 | 9.52e-03 | 28 |
GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
GO:00442722 | Liver | HCC | sulfur compound biosynthetic process | 95/7958 | 148/18723 | 7.89e-08 | 1.58e-06 | 95 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
GO:00442724 | Oral cavity | OSCC | sulfur compound biosynthetic process | 82/7305 | 148/18723 | 3.71e-05 | 3.31e-04 | 82 |
GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLCE | insertion | Frame_Shift_Ins | novel | c.1846_1847insTCTT | p.His616LeufsTer48 | p.H616Lfs*48 | O94923 | protein_coding | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD | ||
GLCE | insertion | Nonsense_Mutation | novel | c.484_485insTATAGTTG | p.Tyr162LeufsTer2 | p.Y162Lfs*2 | O94923 | protein_coding | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
GLCE | insertion | Nonsense_Mutation | novel | c.483_484insTTATAGTTGACCCGAGCTGCCAAGCAACGCA | p.Tyr162LeufsTer2 | p.Y162Lfs*2 | O94923 | protein_coding | TCGA-D1-A0ZU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | ||
GLCE | SNV | Missense_Mutation | novel | c.1279N>C | p.Thr427Pro | p.T427P | O94923 | protein_coding | tolerated(0.27) | probably_damaging(0.943) | TCGA-DD-AAEG-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GLCE | SNV | Missense_Mutation | c.1749N>G | p.Ile583Met | p.I583M | O94923 | protein_coding | deleterious(0) | probably_damaging(0.919) | TCGA-50-6592-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
GLCE | SNV | Missense_Mutation | c.178N>C | p.Glu60Gln | p.E60Q | O94923 | protein_coding | tolerated_low_confidence(0.23) | benign(0) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
GLCE | SNV | Missense_Mutation | novel | c.276N>A | p.Asn92Lys | p.N92K | O94923 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-64-1677-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | gemcitabine | PD |
GLCE | SNV | Missense_Mutation | novel | c.577N>T | p.Gly193Trp | p.G193W | O94923 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-80-5608-01 | Lung | lung adenocarcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
GLCE | SNV | Missense_Mutation | c.511N>A | p.Asp171Asn | p.D171N | O94923 | protein_coding | tolerated(0.53) | benign(0.007) | TCGA-86-8585-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
GLCE | SNV | Missense_Mutation | novel | c.1226N>T | p.Ser409Ile | p.S409I | O94923 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-21-1081-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |